Novo Nordisk reported Phase 3 data showing its combo GLP‑1/amylin candidate CagriSema reduced blood glucose and body weight more than semaglutide (Wegovy) in a large type 2 diabetes trial. In completer analyses CagriSema cut A1c by about 1.9 percentage points and body weight ~14% versus ~1.8 and ~10% for semaglutide; conservative treatment‑regimen estimates also favored CagriSema (1.8 vs 1.7 A1c; 13% vs 9% weight). The company has already sought regulatory clearance in obesity and will lean on this diabetes dataset in filings and competitive positioning against Eli Lilly’s Zepbound. The results sharpen the metabolic drug rivalry and could affect labeling, pricing and payer negotiations if regulators accept the efficacy and safety profile.